Evogene Ltd. Announces Executive Departure Amid Restructuring
Ticker: EVGN · Form: 6-K · Filed: Jan 15, 2025 · CIK: 1574565
Sentiment: neutral
Topics: management-change, restructuring
TL;DR
Evogene's EVP of Biz Dev, Eyal Ronen, is out March 4th due to restructuring. #managementchange
AI Summary
Evogene Ltd. announced that Eyal Ronen, Executive Vice President of Business Development, will be leaving the company effective March 4, 2025, as part of an organizational restructuring. The company expressed gratitude for his contributions.
Why It Matters
Changes in key management personnel can signal shifts in company strategy or operational focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing reports a routine executive departure and organizational restructuring, which is common and does not inherently indicate significant financial or operational risk.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- Eyal Ronen (person) — Executive Vice President of Business Development
FAQ
Who is leaving Evogene Ltd. and what is their role?
Eyal Ronen, the Company's Executive Vice President of Business Development, is leaving Evogene Ltd.
When is Eyal Ronen's last day at Evogene Ltd.?
Eyal Ronen's employment with Evogene Ltd. will conclude effective March 4, 2025.
What is the reason for Eyal Ronen's departure?
Eyal Ronen's departure is part of an organizational restructuring at Evogene Ltd.
What is Evogene Ltd.'s primary business sector?
Evogene Ltd. is in the AGRICULTURE CHEMICALS sector, SIC code 2870.
What form is Evogene Ltd. filing with the SEC?
Evogene Ltd. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
Filing Stats: 291 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2025-01-15 16:00:48
Filing Documents
- zk2532548.htm (6-K) — 9KB
- 0001178913-25-000129.txt ( ) — 11KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS Evogene Ltd., or Evogene, reports changes in the management: As part of an organizational restructuring, Mr. Eyal Ronen, the Company's Executive Vice President of Business Development, will conclude his employment with Evogene, effective March 4, 2025. Evogene expresses its gratitude to Mr. Ronen for his contributions during his tenure. Mr. Ronen's responsibilities will be integrated into the existing management structure, ensuring continuity and further development of our strategic initiatives. The Company remains committed to advancing its business objectives and driving growth through collaborative efforts and innovative solutions. This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration statements on Form F-3 (File No. 333-277565) and on Form S-8 (File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of Evogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. EVOGENE LTD. (Registrant) Date: January 15, 2025 By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer